Kraig Biocraft Laboratories is an early-stage biotech company developing recombinant spider silk fiber for commercial use. Kraig genetically engineers domesticated silkworms to express spider silk proteins alongside native silkworm silk proteins, producing a hybrid fiber that Kraig argues combines the tensile strength, flexibility, and toughness that synthetic performance fibers like aramids (e.g., Kevlar) and UHMWPE (e.g., Dyneema) cannot simultaneously deliver. Target end markets include performance apparel, military and ballistic protection, workwear, filtration, luxury fashion, and medical implants. Kraig's production strategy relies on existing sericulture infrastructure in Vietnam through its wholly owned subsidiary Prodigy Silk, rather than building new facilities, using established local labor and equipment to rear transgenic silkworms and reel cocoons into finished fiber. Kraig intends to sell fiber directly to manufacturers in technical textile and performance apparel markets, and is pursuing collaborative development agreements with channel partners in those end markets. The company is pre-revenue, carries a going concern qualification, and is financing operations primarily through equity issuance. Near-term priorities are improving silkworm robustness in Vietnamese growing conditions, increasing cocoon yields through selective breeding, and developing new transgenic strains with higher-purity spider silk output.